The MBS review branch has set up a dedicated email address for feedback regarding colonoscopy-related items.
The email address is MBSReviews.Colonoscopy@health.gov.au.
The MBS have asked that GESA members write to them at that email address providing details of any MBS-related matters that are of concern.
We urge you to email MBS directly with your concerns including re-sending any emails that you may have previously sent to GESA.
This information will be used when DOH are preparing their 'Frequently Asked Questions and Answers'. It also assists in providing the DOH with a sense of the breadth of issues connected to the implementation. GESA is also happy to receive and collate feedback.
Fact sheets and other downloads relating to the most recent changes to colonoscopy services are available on the 'MBS Online' web site at http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Factsheet-Colonoscopy
GESA has been advised that the pending regulatory changes (including final item descriptors) have now been registered on the Federal Register of Legislation as part of the Health Insurance Legislation Amendment (2019 Measures No. 1) Regulations 2019.
The Medicare Reviews Unit is providing the 'MBS Update' newsletter to help keep stakeholders informed of the progress of the MBS Review. It will be distributed every two months.
To subscribe please email MBSReviews@health.gov.au. You may unsubscribe at any time.
The Medical Services Advisory Committee (MSAC) is an independent non-statutory committee established by the Federal Health Minister in 1998.
MSAC appraises new medical services proposed for public funding, and provides advice to Government on whether a new medical service should be publicly funded (and if so, its circumstances) on an assessment of its comparative safety, clinical effectiveness, cost-effectiveness, and total cost, using the best available evidence.
Amendments and reviews of existing services funded on the Medical Benefits Schedule (MBS) or other programmes (for example, blood products or screening programmes) are also considered by MSAC.
MSAC and the Pharmaceutical Benefits Advisory Committee (PBAC) are both committees supported by respective secretariat branches within the Federal Department of Health.
Once we have more information we will pass that on.